Signs $13 mil. deal with Takara Shuzo for the development of a treatment for IgA nephropathy using Tanox' migis technology, Houston-based Tanox announces Nov. 14. Takara Shuzo, a Japanese brewery with a biotech division specializing in diagnostics and reagents, will pay Tanox an initial license fee, fund R&D, and make milestone payments over four-and- a-half years to equal the $13 mil., more than twice the $6 mil. in cash Tanox now has on hand
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth